PTG Poltreg S.A.
Poltreg S.A., a biotechnology company, researches and develops therapies for autoimmune diseases in Poland. Its product pipeline includes PTG-OO7 + Rituximab which is in phase II clinical trial to treat presymptomatic T1D; MOG CAR-Treg which is in phase I clinical trial for the treatment of multiple sclerosis, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis; Multi-Edit/Allo MOG CAR-Treg which is in preclinical trial to treat multiple sclerosis, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis; and Antigen-specific T-regulatory cell (Tregs) which is in preclinical trial to treat T1D. The company also develops CD6/CTLA4 CAR-Treg which is in phase I clinical trial to treat stage 3 T1D; CD6/CTLA4 CAR-Treg which is in preclinical trial for the treatment of vitiligo, atopic derm, psoriasis, and alopecia areata; CD6/CTLA4 CAR-Treg which is in preclinical trial to treat multiple sclerosis, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis; and PTG-OO7 + Rituximab which is in preclinical trial to treat presympt T1D. In addition, it is developing cell therapies involve the use of human cells to regenerate a patient's damaged tissues or organs. The company was founded in 2015 and is headquartered in Gdansk, Poland.…
Industry Peers
BiotechnologyKey Statistics
About Poltreg (WSE: PTG)
›
Poltreg (WSE: PTG) is listed on Warsaw Stock Exchange, where its shares trade in PLN. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 34 employees.
The shares were at 18.30 PLN on 19 November 2026, down 39.0% over 52 weeks. Its 52-week range is 16.00 PLN to 32.70 PLN: the price is 44.0% below the high and 14.4% above the low.
Its market capitalisation is 108.27M PLN.
Poltreg reports return on equity of -60.0%.
It holds more cash than debt, a net cash position of 15.16M PLN. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 29.30 PLN is 60.1% above the current price.